DENVER, Oct. 21, 2010 (GLOBE NEWSWIRE) -- MusclePharm® Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement company with a proprietary formulation used in its portfolio of performance products, announced today that Ron Sekura, B.S., M.S., PhD., will join MusclePharm board of directors as its Director of Therapeutic Research.
Dr. Sekura will be assisting in the development of the Company's therapeutic indication and application for patients with HIV experiencing catabolic cachexia.
Dr. Sekura commented, "I am very pleased to join the board of MusclePharm as it expands into the field of therapeutic nutritional supplementation for the application of HIV disease. Catabolic cashexia is a wasting condition that is physically devastating and extremely costly to treat. There has not been a great deal of successful response with the current therapeutic options but I believe Musclepharm is properly focusing on solving this condition."
Ron Sekura is currently President of VivoNex LLC and Biotechnology Assessment Services, Inc. Dr. Sekura is the former Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), as well as a former Research Chemist at The National Institute of Child Health and Human Development (NICHD) at the NIH and the Center for Biologics Evaluation and Research (CBER). He received his Bachelor of Science and Master of Science in Biochemistry degrees at Pennsylvania State University and his PhD at Cornell University. Dr. Sekura is the author of over sixty scientific publications.
"We are thrilled to have Dr. Sekura join our Board of Directors. We believe Dr. Sekura's expertise at the FDA and NIAID, as well as his research and work at VivoNex regarding HIV drug adherence, will assist in our endeavor to provide our therapeutic nutritional supplementation, Re-con, to people with HIV experiencing involuntary weight loss, catabolic cachexia and nutrient deficiencies," stated MusclePharm President, Cory Gregory.
MusclePharm is presently preparing their application for Recon to be added to the Medicaid formulary, beginning in New York State for people diagnosed with HIV and AIDS as well as nation-wide Veterans Administration therapeutic formularies. In addition, MusclePharm is exploring the distribution of MusclePharm products, such as Recon, to people living with HIV in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR)."
MusclePharm's Recon Nutritional Supplement contains important amino acids, which assists in reaching the higher levels of nutrition required for people living with HIV. It is easily digestible, helps the absorption of amino acids and proteins. Recon contains essential minerals, digestive enzymes, Glutamine and other metabolic agents that maximize recovery, protein synthesis and endurance.
About MusclePharm Corporation
Headquartered in Denver, Colorado, MusclePharm is a rapidly expanding healthy life-style company that develops and manufacturers a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com. For more information, please visit www.globenewswire.com/newsroom/ctr%3Fd=203004%26l=8%26a=www.musclepharm.com%26u=http%253A%252F%252Fus.lrd.yahoo.com%252F_ylt%253DAh.K98na.C01A13qAgtrooLjba9_%253B_ylu%253DX3oDMTE2Y3Zhc3VmBHBvcwMyBHNlYwNuZXdzYXJ0Ym9keQRzbGsDd3d3bXVzY2xlcGhh%252FSIG%253D16d5jlubp%252F%252A%252Ahttp%25253A%252Fcts.businesswire.com%252Fct%252FCT%25253Fid%253Dsmartlink%252526url%253Dhttp%2525253A%2525252F%2525252Fwww.musclepharm.com%252526esheet%253D6338688%252526lan%253Den-US%252526anchor%253Dwww.musclepharm.com%252526index%253D2%252526md5%253D39d61eeacbdb7d5271eb6d35c6bd289c">www.musclepharm.com.
Forward-looking Statements
MusclePharm Corporation believes the information set forth in this Press Release may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in "Risk Factors" in Item2.02 of the Company's Form 8-K dated February 18, 2010, which has been filed with the Securities and Exchange Commission.